Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Identifieur interne : 000814 ( PubMed/Checkpoint ); précédent : 000813; suivant : 000815Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Auteurs : Jeffrey E. Gershenwald [États-Unis] ; Richard A. Scolyer [Australie] ; Kenneth R. Hess [États-Unis] ; Vernon K. Sondak [États-Unis] ; Georgina V. Long [Australie] ; Merrick I. Ross [États-Unis] ; Alexander J. Lazar [États-Unis] ; Mark B. Faries [États-Unis] ; John M. Kirkwood [États-Unis] ; Grant A. Mcarthur [Australie] ; Lauren E. Haydu [États-Unis] ; Alexander M M. Eggermont [France] ; Keith T. Flaherty [États-Unis] ; Charles M. Balch [États-Unis] ; John F. Thompson [Australie]Source :
- CA: a cancer journal for clinicians [ 1542-4863 ] ; 2017.
Descripteurs français
- KwdFr :
- Enregistrements, Guides de bonnes pratiques cliniques comme sujet, Humains, Mélanome (anatomopathologie), Mélanome (épidémiologie), Métastase lymphatique, Sociétés médicales, Stade de la tumeur (normes), Tumeurs cutanées (anatomopathologie), Tumeurs cutanées (épidémiologie), États-Unis d'Amérique (épidémiologie).
- MESH :
- anatomopathologie : Mélanome, Tumeurs cutanées.
- normes : Stade de la tumeur.
- épidémiologie : Mélanome, Tumeurs cutanées, États-Unis d'Amérique.
- Enregistrements, Guides de bonnes pratiques cliniques comme sujet, Humains, Métastase lymphatique, Sociétés médicales.
English descriptors
- KwdEn :
- MESH :
- epidemiology : Melanoma, Skin Neoplasms, United States.
- pathology : Melanoma, Skin Neoplasms.
- standards : Neoplasm Staging.
- Humans, Lymphatic Metastasis, Practice Guidelines as Topic, Registries, Societies, Medical.
Abstract
Answer questions and earn CME/CNE To update the melanoma staging system of the American Joint Committee on Cancer (AJCC) a large database was assembled comprising >46,000 patients from 10 centers worldwide with stages I, II, and III melanoma diagnosed since 1998. Based on analyses of this new database, the existing seventh edition AJCC stage IV database, and contemporary clinical trial data, the AJCC Melanoma Expert Panel introduced several important changes to the Tumor, Nodes, Metastasis (TNM) classification and stage grouping criteria. Key changes in the eighth edition AJCC Cancer Staging Manual include: 1) tumor thickness measurements to be recorded to the nearest 0.1 mm, not 0.01 mm; 2) definitions of T1a and T1b are revised (T1a, <0.8 mm without ulceration; T1b, 0.8-1.0 mm with or without ulceration or <0.8 mm with ulceration), with mitotic rate no longer a T category criterion; 3) pathological (but not clinical) stage IA is revised to include T1b N0 M0 (formerly pathologic stage IB); 4) the N category descriptors "microscopic" and "macroscopic" for regional node metastasis are redefined as "clinically occult" and "clinically apparent"; 5) prognostic stage III groupings are based on N category criteria and T category criteria (ie, primary tumor thickness and ulceration) and increased from 3 to 4 subgroups (stages IIIA-IIID); 6) definitions of N subcategories are revised, with the presence of microsatellites, satellites, or in-transit metastases now categorized as N1c, N2c, or N3c based on the number of tumor-involved regional lymph nodes, if any; 7) descriptors are added to each M1 subcategory designation for lactate dehydrogenase (LDH) level (LDH elevation no longer upstages to M1c); and 8) a new M1d designation is added for central nervous system metastases. This evidence-based revision of the AJCC melanoma staging system will guide patient treatment, provide better prognostic estimates, and refine stratification of patients entering clinical trials. CA Cancer J Clin 2017;67:472-492. © 2017 American Cancer Society.
DOI: 10.3322/caac.21409
PubMed: 29028110
Affiliations:
- Australie, France, États-Unis
- Californie, Floride, Massachusetts, Nouvelle-Galles du Sud, Pennsylvanie, Texas
- Sydney
- Université de Sydney
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:29028110Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.</title><author><name sortKey="Gershenwald, Jeffrey E" sort="Gershenwald, Jeffrey E" uniqKey="Gershenwald J" first="Jeffrey E" last="Gershenwald">Jeffrey E. Gershenwald</name><affiliation wicri:level="2"><nlm:affiliation>Professor of Surgery and Cancer Biology, Department of Surgical Oncology; Medical Director, Melanoma and Skin Center, The University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Professor of Surgery and Cancer Biology, Department of Surgical Oncology; Medical Director, Melanoma and Skin Center, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Scolyer, Richard A" sort="Scolyer, Richard A" uniqKey="Scolyer R" first="Richard A" last="Scolyer">Richard A. Scolyer</name><affiliation wicri:level="4"><nlm:affiliation>Conjoint Medical Director, Melanoma Institute Australia; Clinical Professor, The University of Sydney, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Conjoint Medical Director, Melanoma Institute Australia; Clinical Professor, The University of Sydney, Sydney, New South Wales</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Hess, Kenneth R" sort="Hess, Kenneth R" uniqKey="Hess K" first="Kenneth R" last="Hess">Kenneth R. Hess</name><affiliation wicri:level="2"><nlm:affiliation>Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Sondak, Vernon K" sort="Sondak, Vernon K" uniqKey="Sondak V" first="Vernon K" last="Sondak">Vernon K. Sondak</name><affiliation wicri:level="2"><nlm:affiliation>Chair, Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>Chair, Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa</wicri:cityArea></affiliation></author><author><name sortKey="Long, Georgina V" sort="Long, Georgina V" uniqKey="Long G" first="Georgina V" last="Long">Georgina V. Long</name><affiliation wicri:level="1"><nlm:affiliation>Conjoint Medical Director and Chair of Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia, The University of Sydney and Royal North Shore Hospital, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Conjoint Medical Director and Chair of Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia, The University of Sydney and Royal North Shore Hospital, Sydney, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author><author><name sortKey="Ross, Merrick I" sort="Ross, Merrick I" uniqKey="Ross M" first="Merrick I" last="Ross">Merrick I. Ross</name><affiliation wicri:level="2"><nlm:affiliation>Professor of Surgery, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Professor of Surgery, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Lazar, Alexander J" sort="Lazar, Alexander J" uniqKey="Lazar A" first="Alexander J" last="Lazar">Alexander J. Lazar</name><affiliation wicri:level="2"><nlm:affiliation>Professor of Pathology, Dermatology, and Translational Molecular Pathology; Director, Melanoma Molecular Diagnostics, The University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Professor of Pathology, Dermatology, and Translational Molecular Pathology; Director, Melanoma Molecular Diagnostics, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Faries, Mark B" sort="Faries, Mark B" uniqKey="Faries M" first="Mark B" last="Faries">Mark B. Faries</name><affiliation wicri:level="2"><nlm:affiliation>Co-Director, Melanoma Program; Head, Surgical Oncology, The Angeles Clinic and Research Institute, Los Angeles, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Co-Director, Melanoma Program; Head, Surgical Oncology, The Angeles Clinic and Research Institute, Los Angeles</wicri:cityArea></affiliation></author><author><name sortKey="Kirkwood, John M" sort="Kirkwood, John M" uniqKey="Kirkwood J" first="John M" last="Kirkwood">John M. Kirkwood</name><affiliation wicri:level="2"><nlm:affiliation>Professor of Medicine, Dermatology, and Translational Science, The University of Pittsburgh School of Medicine, Pittsburgh, PA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Professor of Medicine, Dermatology, and Translational Science, The University of Pittsburgh School of Medicine, Pittsburgh</wicri:cityArea></affiliation></author><author><name sortKey="Mcarthur, Grant A" sort="Mcarthur, Grant A" uniqKey="Mcarthur G" first="Grant A" last="Mcarthur">Grant A. Mcarthur</name><affiliation wicri:level="1"><nlm:affiliation>Executive Director, Victorian Comprehensive Cancer Center, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Executive Director, Victorian Comprehensive Cancer Center, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Haydu, Lauren E" sort="Haydu, Lauren E" uniqKey="Haydu L" first="Lauren E" last="Haydu">Lauren E. Haydu</name><affiliation wicri:level="2"><nlm:affiliation>Manager, Clinical Data Management Systems, The University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Manager, Clinical Data Management Systems, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Eggermont, Alexander M M" sort="Eggermont, Alexander M M" uniqKey="Eggermont A" first="Alexander M M" last="Eggermont">Alexander M M. Eggermont</name><affiliation wicri:level="1"><nlm:affiliation>Director General, Gustave Roussy Cancer Institute, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Director General, Gustave Roussy Cancer Institute, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Flaherty, Keith T" sort="Flaherty, Keith T" uniqKey="Flaherty K" first="Keith T" last="Flaherty">Keith T. Flaherty</name><affiliation wicri:level="2"><nlm:affiliation>Director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, Boston, MA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Balch, Charles M" sort="Balch, Charles M" uniqKey="Balch C" first="Charles M" last="Balch">Charles M. Balch</name><affiliation wicri:level="2"><nlm:affiliation>Professor of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Professor of Surgery, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Thompson, John F" sort="Thompson, John F" uniqKey="Thompson J" first="John F" last="Thompson">John F. Thompson</name><affiliation wicri:level="1"><nlm:affiliation>Professor of Melanoma and Surgical Oncology, Melanoma Institute Australia, The University of Sydney and Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Professor of Melanoma and Surgical Oncology, Melanoma Institute Australia, The University of Sydney and Royal Prince Alfred Hospital, Sydney, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:29028110</idno><idno type="pmid">29028110</idno><idno type="doi">10.3322/caac.21409</idno><idno type="wicri:Area/PubMed/Corpus">000161</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000161</idno><idno type="wicri:Area/PubMed/Curation">000161</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000161</idno><idno type="wicri:Area/PubMed/Checkpoint">000161</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000161</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.</title><author><name sortKey="Gershenwald, Jeffrey E" sort="Gershenwald, Jeffrey E" uniqKey="Gershenwald J" first="Jeffrey E" last="Gershenwald">Jeffrey E. Gershenwald</name><affiliation wicri:level="2"><nlm:affiliation>Professor of Surgery and Cancer Biology, Department of Surgical Oncology; Medical Director, Melanoma and Skin Center, The University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Professor of Surgery and Cancer Biology, Department of Surgical Oncology; Medical Director, Melanoma and Skin Center, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Scolyer, Richard A" sort="Scolyer, Richard A" uniqKey="Scolyer R" first="Richard A" last="Scolyer">Richard A. Scolyer</name><affiliation wicri:level="4"><nlm:affiliation>Conjoint Medical Director, Melanoma Institute Australia; Clinical Professor, The University of Sydney, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Conjoint Medical Director, Melanoma Institute Australia; Clinical Professor, The University of Sydney, Sydney, New South Wales</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Hess, Kenneth R" sort="Hess, Kenneth R" uniqKey="Hess K" first="Kenneth R" last="Hess">Kenneth R. Hess</name><affiliation wicri:level="2"><nlm:affiliation>Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Sondak, Vernon K" sort="Sondak, Vernon K" uniqKey="Sondak V" first="Vernon K" last="Sondak">Vernon K. Sondak</name><affiliation wicri:level="2"><nlm:affiliation>Chair, Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>Chair, Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa</wicri:cityArea></affiliation></author><author><name sortKey="Long, Georgina V" sort="Long, Georgina V" uniqKey="Long G" first="Georgina V" last="Long">Georgina V. Long</name><affiliation wicri:level="1"><nlm:affiliation>Conjoint Medical Director and Chair of Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia, The University of Sydney and Royal North Shore Hospital, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Conjoint Medical Director and Chair of Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia, The University of Sydney and Royal North Shore Hospital, Sydney, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author><author><name sortKey="Ross, Merrick I" sort="Ross, Merrick I" uniqKey="Ross M" first="Merrick I" last="Ross">Merrick I. Ross</name><affiliation wicri:level="2"><nlm:affiliation>Professor of Surgery, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Professor of Surgery, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Lazar, Alexander J" sort="Lazar, Alexander J" uniqKey="Lazar A" first="Alexander J" last="Lazar">Alexander J. Lazar</name><affiliation wicri:level="2"><nlm:affiliation>Professor of Pathology, Dermatology, and Translational Molecular Pathology; Director, Melanoma Molecular Diagnostics, The University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Professor of Pathology, Dermatology, and Translational Molecular Pathology; Director, Melanoma Molecular Diagnostics, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Faries, Mark B" sort="Faries, Mark B" uniqKey="Faries M" first="Mark B" last="Faries">Mark B. Faries</name><affiliation wicri:level="2"><nlm:affiliation>Co-Director, Melanoma Program; Head, Surgical Oncology, The Angeles Clinic and Research Institute, Los Angeles, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Co-Director, Melanoma Program; Head, Surgical Oncology, The Angeles Clinic and Research Institute, Los Angeles</wicri:cityArea></affiliation></author><author><name sortKey="Kirkwood, John M" sort="Kirkwood, John M" uniqKey="Kirkwood J" first="John M" last="Kirkwood">John M. Kirkwood</name><affiliation wicri:level="2"><nlm:affiliation>Professor of Medicine, Dermatology, and Translational Science, The University of Pittsburgh School of Medicine, Pittsburgh, PA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Professor of Medicine, Dermatology, and Translational Science, The University of Pittsburgh School of Medicine, Pittsburgh</wicri:cityArea></affiliation></author><author><name sortKey="Mcarthur, Grant A" sort="Mcarthur, Grant A" uniqKey="Mcarthur G" first="Grant A" last="Mcarthur">Grant A. Mcarthur</name><affiliation wicri:level="1"><nlm:affiliation>Executive Director, Victorian Comprehensive Cancer Center, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Executive Director, Victorian Comprehensive Cancer Center, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Haydu, Lauren E" sort="Haydu, Lauren E" uniqKey="Haydu L" first="Lauren E" last="Haydu">Lauren E. Haydu</name><affiliation wicri:level="2"><nlm:affiliation>Manager, Clinical Data Management Systems, The University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Manager, Clinical Data Management Systems, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Eggermont, Alexander M M" sort="Eggermont, Alexander M M" uniqKey="Eggermont A" first="Alexander M M" last="Eggermont">Alexander M M. Eggermont</name><affiliation wicri:level="1"><nlm:affiliation>Director General, Gustave Roussy Cancer Institute, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Director General, Gustave Roussy Cancer Institute, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Flaherty, Keith T" sort="Flaherty, Keith T" uniqKey="Flaherty K" first="Keith T" last="Flaherty">Keith T. Flaherty</name><affiliation wicri:level="2"><nlm:affiliation>Director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, Boston, MA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Balch, Charles M" sort="Balch, Charles M" uniqKey="Balch C" first="Charles M" last="Balch">Charles M. Balch</name><affiliation wicri:level="2"><nlm:affiliation>Professor of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Professor of Surgery, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Thompson, John F" sort="Thompson, John F" uniqKey="Thompson J" first="John F" last="Thompson">John F. Thompson</name><affiliation wicri:level="1"><nlm:affiliation>Professor of Melanoma and Surgical Oncology, Melanoma Institute Australia, The University of Sydney and Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Professor of Melanoma and Surgical Oncology, Melanoma Institute Australia, The University of Sydney and Royal Prince Alfred Hospital, Sydney, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author></analytic><series><title level="j">CA: a cancer journal for clinicians</title><idno type="eISSN">1542-4863</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Humans</term><term>Lymphatic Metastasis</term><term>Melanoma (epidemiology)</term><term>Melanoma (pathology)</term><term>Neoplasm Staging (standards)</term><term>Practice Guidelines as Topic</term><term>Registries</term><term>Skin Neoplasms (epidemiology)</term><term>Skin Neoplasms (pathology)</term><term>Societies, Medical</term><term>United States (epidemiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Enregistrements</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Mélanome (anatomopathologie)</term><term>Mélanome (épidémiologie)</term><term>Métastase lymphatique</term><term>Sociétés médicales</term><term>Stade de la tumeur (normes)</term><term>Tumeurs cutanées (anatomopathologie)</term><term>Tumeurs cutanées (épidémiologie)</term><term>États-Unis d'Amérique (épidémiologie)</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Mélanome</term><term>Tumeurs cutanées</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Melanoma</term><term>Skin Neoplasms</term><term>United States</term></keywords><keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Stade de la tumeur</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Melanoma</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Neoplasm Staging</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Mélanome</term><term>Tumeurs cutanées</term><term>États-Unis d'Amérique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Lymphatic Metastasis</term><term>Practice Guidelines as Topic</term><term>Registries</term><term>Societies, Medical</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Enregistrements</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Métastase lymphatique</term><term>Sociétés médicales</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Answer questions and earn CME/CNE To update the melanoma staging system of the American Joint Committee on Cancer (AJCC) a large database was assembled comprising >46,000 patients from 10 centers worldwide with stages I, II, and III melanoma diagnosed since 1998. Based on analyses of this new database, the existing seventh edition AJCC stage IV database, and contemporary clinical trial data, the AJCC Melanoma Expert Panel introduced several important changes to the Tumor, Nodes, Metastasis (TNM) classification and stage grouping criteria. Key changes in the eighth edition AJCC Cancer Staging Manual include: 1) tumor thickness measurements to be recorded to the nearest 0.1 mm, not 0.01 mm; 2) definitions of T1a and T1b are revised (T1a, <0.8 mm without ulceration; T1b, 0.8-1.0 mm with or without ulceration or <0.8 mm with ulceration), with mitotic rate no longer a T category criterion; 3) pathological (but not clinical) stage IA is revised to include T1b N0 M0 (formerly pathologic stage IB); 4) the N category descriptors "microscopic" and "macroscopic" for regional node metastasis are redefined as "clinically occult" and "clinically apparent"; 5) prognostic stage III groupings are based on N category criteria and T category criteria (ie, primary tumor thickness and ulceration) and increased from 3 to 4 subgroups (stages IIIA-IIID); 6) definitions of N subcategories are revised, with the presence of microsatellites, satellites, or in-transit metastases now categorized as N1c, N2c, or N3c based on the number of tumor-involved regional lymph nodes, if any; 7) descriptors are added to each M1 subcategory designation for lactate dehydrogenase (LDH) level (LDH elevation no longer upstages to M1c); and 8) a new M1d designation is added for central nervous system metastases. This evidence-based revision of the AJCC melanoma staging system will guide patient treatment, provide better prognostic estimates, and refine stratification of patients entering clinical trials. CA Cancer J Clin 2017;67:472-492. © 2017 American Cancer Society.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29028110</PMID><DateCreated><Year>2017</Year><Month>10</Month><Day>13</Day></DateCreated><DateCompleted><Year>2017</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1542-4863</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>Nov</Month></PubDate></JournalIssue><Title>CA: a cancer journal for clinicians</Title><ISOAbbreviation>CA Cancer J Clin</ISOAbbreviation></Journal><ArticleTitle>Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.</ArticleTitle><Pagination><MedlinePgn>472-492</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3322/caac.21409</ELocationID><Abstract><AbstractText>Answer questions and earn CME/CNE To update the melanoma staging system of the American Joint Committee on Cancer (AJCC) a large database was assembled comprising >46,000 patients from 10 centers worldwide with stages I, II, and III melanoma diagnosed since 1998. Based on analyses of this new database, the existing seventh edition AJCC stage IV database, and contemporary clinical trial data, the AJCC Melanoma Expert Panel introduced several important changes to the Tumor, Nodes, Metastasis (TNM) classification and stage grouping criteria. Key changes in the eighth edition AJCC Cancer Staging Manual include: 1) tumor thickness measurements to be recorded to the nearest 0.1 mm, not 0.01 mm; 2) definitions of T1a and T1b are revised (T1a, <0.8 mm without ulceration; T1b, 0.8-1.0 mm with or without ulceration or <0.8 mm with ulceration), with mitotic rate no longer a T category criterion; 3) pathological (but not clinical) stage IA is revised to include T1b N0 M0 (formerly pathologic stage IB); 4) the N category descriptors "microscopic" and "macroscopic" for regional node metastasis are redefined as "clinically occult" and "clinically apparent"; 5) prognostic stage III groupings are based on N category criteria and T category criteria (ie, primary tumor thickness and ulceration) and increased from 3 to 4 subgroups (stages IIIA-IIID); 6) definitions of N subcategories are revised, with the presence of microsatellites, satellites, or in-transit metastases now categorized as N1c, N2c, or N3c based on the number of tumor-involved regional lymph nodes, if any; 7) descriptors are added to each M1 subcategory designation for lactate dehydrogenase (LDH) level (LDH elevation no longer upstages to M1c); and 8) a new M1d designation is added for central nervous system metastases. This evidence-based revision of the AJCC melanoma staging system will guide patient treatment, provide better prognostic estimates, and refine stratification of patients entering clinical trials. CA Cancer J Clin 2017;67:472-492. © 2017 American Cancer Society.</AbstractText><CopyrightInformation>© 2017 American Cancer Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gershenwald</LastName><ForeName>Jeffrey E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-4519-5369</Identifier><AffiliationInfo><Affiliation>Professor of Surgery and Cancer Biology, Department of Surgical Oncology; Medical Director, Melanoma and Skin Center, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scolyer</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Conjoint Medical Director, Melanoma Institute Australia; Clinical Professor, The University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Senior Staff Pathologist, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hess</LastName><ForeName>Kenneth R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sondak</LastName><ForeName>Vernon K</ForeName><Initials>VK</Initials><AffiliationInfo><Affiliation>Chair, Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Georgina V</ForeName><Initials>GV</Initials><AffiliationInfo><Affiliation>Conjoint Medical Director and Chair of Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia, The University of Sydney and Royal North Shore Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Merrick I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Professor of Surgery, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazar</LastName><ForeName>Alexander J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Professor of Pathology, Dermatology, and Translational Molecular Pathology; Director, Melanoma Molecular Diagnostics, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faries</LastName><ForeName>Mark B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Co-Director, Melanoma Program; Head, Surgical Oncology, The Angeles Clinic and Research Institute, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirkwood</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Professor of Medicine, Dermatology, and Translational Science, The University of Pittsburgh School of Medicine, Pittsburgh, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McArthur</LastName><ForeName>Grant A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Executive Director, Victorian Comprehensive Cancer Center, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haydu</LastName><ForeName>Lauren E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Manager, Clinical Data Management Systems, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eggermont</LastName><ForeName>Alexander M M</ForeName><Initials>AMM</Initials><AffiliationInfo><Affiliation>Director General, Gustave Roussy Cancer Institute, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flaherty</LastName><ForeName>Keith T</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balch</LastName><ForeName>Charles M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Professor of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>John F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Professor of Melanoma and Surgical Oncology, Melanoma Institute Australia, The University of Sydney and Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>CA Cancer J Clin</MedlineTA><NlmUniqueID>0370647</NlmUniqueID><ISSNLinking>0007-9235</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012955" MajorTopicYN="N">Societies, Medical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">American Joint Committee on Cancer (AJCC)</Keyword><Keyword MajorTopicYN="N">TNM classification</Keyword><Keyword MajorTopicYN="N">melanoma</Keyword><Keyword MajorTopicYN="N">metastasis</Keyword><Keyword MajorTopicYN="N">pathology</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">staging</Keyword><Keyword MajorTopicYN="N">survival</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Gershenwald</LastName><ForeName>Jeffrey E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scolyer</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Atkins</LastName><ForeName>Michael B</ForeName><Initials>MB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Balch</LastName><ForeName>Charles M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barnhill</LastName><ForeName>Raymond L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bilimoria</LastName><ForeName>Karl Y</ForeName><Initials>KY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buzaid</LastName><ForeName>Antonio C</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Byrd</LastName><ForeName>David R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cochran</LastName><ForeName>Alistair J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eggermont</LastName><ForeName>Alexander M M</ForeName><Initials>AMM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elder</LastName><ForeName>David E</ForeName><Initials>DE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faries</LastName><ForeName>Mark B</ForeName><Initials>MB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flaherty</LastName><ForeName>Keith T</ForeName><Initials>KT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garbe</LastName><ForeName>Claus</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gardner</LastName><ForeName>Julie M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gimotty</LastName><ForeName>Phyllis A</ForeName><Initials>PA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Halpern</LastName><ForeName>Allan C</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haydu</LastName><ForeName>Lauren E</ForeName><Initials>LE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hess</LastName><ForeName>Kenneth R</ForeName><Initials>KR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kirkwood</LastName><ForeName>John M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lazar</LastName><ForeName>Alexander J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Anne W M</ForeName><Initials>AWM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Long</LastName><ForeName>Georgina V</ForeName><Initials>GV</Initials></Investigator><Investigator ValidYN="Y"><LastName>McArthur</LastName><ForeName>Grant A</ForeName><Initials>GA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mihm</LastName><ForeName>Martin C</ForeName><Initials>MC</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Prieto</LastName><ForeName>Victor G</ForeName><Initials>VG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ross</LastName><ForeName>Merrick I</ForeName><Initials>MI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sober</LastName><ForeName>Arthur J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sondak</LastName><ForeName>Vernon K</ForeName><Initials>VK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>John F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wong</LastName><ForeName>Sandra L</ForeName><Initials>SL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delman</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santinami</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maurichi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nagore</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faries</LastName><ForeName>Mark B</ForeName><Initials>MB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>John F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scolyer</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>McArthur</LastName><ForeName>Grant A</ForeName><Initials>GA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gyorki</LastName><ForeName>David E</ForeName><Initials>DE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henderson</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stratigos</LastName><ForeName>Alexander J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gogas</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gershenwald</LastName><ForeName>Jeffrey E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haydu</LastName><ForeName>Lauren E</ForeName><Initials>LE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rossi</LastName><ForeName>Carlo Riccardo</ForeName><Initials>CR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sommariva</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>06</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>08</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>08</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29028110</ArticleId><ArticleId IdType="doi">10.3322/caac.21409</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>France</li><li>États-Unis</li></country><region><li>Californie</li><li>Floride</li><li>Massachusetts</li><li>Nouvelle-Galles du Sud</li><li>Pennsylvanie</li><li>Texas</li></region><settlement><li>Sydney</li></settlement><orgName><li>Université de Sydney</li></orgName></list><tree><country name="États-Unis"><region name="Texas"><name sortKey="Gershenwald, Jeffrey E" sort="Gershenwald, Jeffrey E" uniqKey="Gershenwald J" first="Jeffrey E" last="Gershenwald">Jeffrey E. Gershenwald</name></region><name sortKey="Balch, Charles M" sort="Balch, Charles M" uniqKey="Balch C" first="Charles M" last="Balch">Charles M. Balch</name><name sortKey="Faries, Mark B" sort="Faries, Mark B" uniqKey="Faries M" first="Mark B" last="Faries">Mark B. Faries</name><name sortKey="Flaherty, Keith T" sort="Flaherty, Keith T" uniqKey="Flaherty K" first="Keith T" last="Flaherty">Keith T. Flaherty</name><name sortKey="Haydu, Lauren E" sort="Haydu, Lauren E" uniqKey="Haydu L" first="Lauren E" last="Haydu">Lauren E. Haydu</name><name sortKey="Hess, Kenneth R" sort="Hess, Kenneth R" uniqKey="Hess K" first="Kenneth R" last="Hess">Kenneth R. Hess</name><name sortKey="Kirkwood, John M" sort="Kirkwood, John M" uniqKey="Kirkwood J" first="John M" last="Kirkwood">John M. Kirkwood</name><name sortKey="Lazar, Alexander J" sort="Lazar, Alexander J" uniqKey="Lazar A" first="Alexander J" last="Lazar">Alexander J. Lazar</name><name sortKey="Ross, Merrick I" sort="Ross, Merrick I" uniqKey="Ross M" first="Merrick I" last="Ross">Merrick I. Ross</name><name sortKey="Sondak, Vernon K" sort="Sondak, Vernon K" uniqKey="Sondak V" first="Vernon K" last="Sondak">Vernon K. Sondak</name></country><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Scolyer, Richard A" sort="Scolyer, Richard A" uniqKey="Scolyer R" first="Richard A" last="Scolyer">Richard A. Scolyer</name></region><name sortKey="Long, Georgina V" sort="Long, Georgina V" uniqKey="Long G" first="Georgina V" last="Long">Georgina V. Long</name><name sortKey="Mcarthur, Grant A" sort="Mcarthur, Grant A" uniqKey="Mcarthur G" first="Grant A" last="Mcarthur">Grant A. Mcarthur</name><name sortKey="Thompson, John F" sort="Thompson, John F" uniqKey="Thompson J" first="John F" last="Thompson">John F. Thompson</name></country><country name="France"><noRegion><name sortKey="Eggermont, Alexander M M" sort="Eggermont, Alexander M M" uniqKey="Eggermont A" first="Alexander M M" last="Eggermont">Alexander M M. Eggermont</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000814 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000814 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:29028110
|texte= Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:29028110" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |